Minodora Mazur

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

René Westhovens, Peter C. Taylor, Rieke Alten et al. · Annals of the Rheumatic Diseases · 2016 · 227 citations · Full text

IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study

Frédéric Houssiau, Aikaterini Thanou, Minodora Mazur et al. · Annals of the Rheumatic Diseases · 2019 · 106 citations · Full text

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn et al. · Arthritis & Rheumatology · 2017 · 75 citations · Full text

OP0263 Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial

Frédéric Vanhoutte, Minodora Mazur, Florence Namour et al. · Annals of the Rheumatic Diseases · 2012 · 14 citations

OP0224 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study

René Westhovens, R. Alten, F.E. Enriquez Sosa et al. · Annals of the Rheumatic Diseases · 2016 · 14 citations